Retinitis pigmentosa (RP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Retinitis pigmentosa (RP)

Retinitis pigmentosa (RP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Retinitis pigmentosa (RP) comprises a large group of inherited vision disorders that cause progressive degeneration of the retina, the light sensitive membrane that coats the inside of the eyes. Retinitis pigmentosa is a group of hereditary progressive disorders that may be inherited as autosomal recessive, autosomal dominant or X-linked recessive traits. The RP11 gene (PRPF31) causing autosomal dominant RP.

Epidemiology- According to Thelansis, It is generally estimated that the disorder affects roughly 1 in 4,000 people, both in the United States and worldwide.

Competitive landscape of Retinitis pigmentosa (RP) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Retinitis pigmentosa (RP) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Retinitis pigmentosa (RP) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Retinitis pigmentosa (RP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        AAV2/5-RPGR        MeiraGTx UK II Ltd        Phase 2

2        CPK850        Novartis Pharmaceuticals        Phase 2

3        BS01        Bionic Sight LLC        Phase 2

4        AAV2/5-hPDE6B        Horama S.A.        Phase 2

5        RST-001        Allergan        Phase 2

6        hRPC        ReNeuron Limited        Phase 2

7        4D-125 IVT Injection        4D Molecular Therapeutics        Phase 2

8        rAAV2tYF-GRK1-RPGR        Applied Genetic Technologies Corp        Phase 2

9        NT-501        Neurotech Pharmaceuticals        Phase 2

10        Minocycline        The Emmes Company, LLC        Phase 2

11        vMCO-I        Nanoscope Therapeutics Inc.        Phase 2

12        rhNGF 180 µg/ml        Dompé Farmaceutici S.p.A        Phase 2

13        QR-1123        ProQR Therapeutics        Phase 2

14        NPI-001        Nacuity Pharmaceuticals, Inc.        Phase 2"